• This month’s E-Reimbursement Newsletter breaks down recent ACA enrollee cancellations and subsidy changes, updates on Medicare drug price negotiation rounds and MFN pricing models, upcoming 15% annual Medicare lab fee schedule cuts, and the late-released Q4 OPPS drug status and coding changes. Read the full newsletter to stay informed on these shifting regulations and keep your Chargemasters up to date.

Read More

Corporate Member News

• Amgen has updated the IMDELLTRA® prescribing information for adults with extensive-stage small cell lung cancer (ES-SCLC) that has progressed on or after platinum-based chemotherapy. 

Read More

• The FDA approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.

Read More

• Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study.

Read More